Real-World Outcome of Platinum-Based Chemotherapy in Advanced Breast Cancer (ABC): A Retrospective Study from a Tertiary Cancer Center in India

Abstract

Introduction There is a paucity of data on platinum-based chemotherapy in advanced breast cancer (ABC) from developing countries like India.

Objectives The objectives were to analyze the efficacy and safety of platinum-based chemotherapy in patients with ABC.

Materials and Methods This was a retrospective study of 35 patients with ABC who were treated with platinum-based chemotherapy (gemcitabine and carboplatin, [GC]) in a tertiary cancer center in India from August 2015 to November 2019. The inclusion criteria were patients with ABC, who had received palliative chemotherapy with GC. The exclusion criteria were patients who had received less than two cycles of GC and patients who received platinum-based chemotherapy for neuroendocrine carcinoma of the breast.

Results The median age was 45 years (range: 28–68 years). All patients were female (97%) except one male (3%). The histology was ductal carcinoma (77%), mixed (17%), and others (6%). Out of the 12 patients tested for breast cancer (BRCA) gene mutation, six patients had a BRCA mutation. Patients with metastatic and locally progressive disease were 91 and 9%, respectively. The median number of prior lines of systemic therapy for metastatic disease was 1 (range: 0–5). The median number of sites of metastasis was 2 (range: 0–5). Patients with visceral crises were 23%. The median number of cycles of GC chemotherapy received was 6 (range: 2–6). A dose reduction in chemotherapy was done in 74%. The responses among 34 evaluable patients were complete response (11%), partial response (24%), stable disease (41%), and progressive disease (24%). Grade 3 or more hematological and nonhematological toxicities were observed in 69 and 9%, respectively. The median progression-free survival and overall survival were 6 and 8 months, respectively. The 1-year progression-free survival and overall survival were 19 and 34%, respectively. Multivariate analysis showed that patients who had received more than 3 cycles had a better outcome.

Conclusion GC was an active and well-tolerated regimen in ABC regardless of the receptor status. Further prospective randomized studies are warranted to assess the optimal regimen in patients with triple-negative breast cancer.

Keywords

advanced breast cancer - platinum-based chemotherapy - real-world outcome

Presentation

This study has not been presented in any meeting.

Registration Number

Not applicable as it is not a clinical trial.

Authors' Contribution

Conception (Indhuja Muthiah Vaikundaraja, Manikandan Dhanushkodi)/acquisition (Indhuja Muthiah Vaikundaraja, Manikandan Dhanushkodi)/analysis (Indhuja Muthiah Vaikundaraja, Manikandan Dhanushkodi, Venkatraman Radhakrishnan, Jayachandran Perumal Kalaiarasi, Nikita Mehra, Arun Kumar Rajan, Gangothri Selvarajan, Siva Sree Kesana, Balasubramanian Ananthi, Priya Iyer, Manjula Rao, Arvind Krishnamurthy, Sridevi Velusamy, Rama Ranganathan, Tenali Gnana Sagar). All authors made substantial contribution toward drafting and final approval and agreed to be accountable on all aspects of the manuscript.

Publikationsverlauf

Artikel online veröffentlicht:
11. Dezember 2021

• References

• 1 Loibl S, O'Shaughnessy J, Untch M. et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 2018; 19 (04) 497-509
• 2 Slamon D, Eiermann W, Robert N. et al; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365 (14) 1273-1283
• 3 Shamseddine AI, Farhat FS. Platinum-based compounds for the treatment of metastatic breast cancer. Chemotherapy 2011; 57 (06) 468-487
• 4 Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 2004; 30 (01) 53-81
• 5 breast_risk.pdf, https://www.nccn.org/professionals/physician_gls/pdf/breast_risk.pdf. Accessed July 17, 2021
• 6 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
• 7 Common Terminology Criteria for Adverse Events (CTCAE). 79 (2009), https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf. Accessed July 17, 2021
• 8 Simmons C, Miller N, Geddie W. et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009; 20 (09) 1499-1504
• 9 Sharma M, Gogia A, Deo SSV, Mathur S. Role of rebiopsy in metastatic breast cancer at progression. Curr Probl Cancer 2019; 43 (05) 438-442
• 10 Anand A, Jacob LA, Lakshmaiah KC. et al. Repeat biopsy a must in recurrent breast cancer: a study from tertiary cancer centre in India. Ann Oncol 2018; 29: ix16-ix17
• 11 Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009; 2009 (02) CD003372
• 12 Dear RF, McGeechan K, Jenkins MC, Barratt A, Tattersall MH, Wilcken N. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2013; CD008792 (12) CD008792
• 13 Maisano R, Zavettieri M, Azzarello D. et al. Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study. J Chemother 2011; 23 (01) 40-43
• 14 Maka VV, Panchal H, Shukla SN, Talati SS. Department of Medical Oncology Gujarat Cancer and Research Institute Ahmedabad Gujarat India. Platinum-based chemotherapy in metastatic triple negative breast cancer: experience of a tertiary referral centre in India. Gulf J Oncolog 2015; 1 (17) 52-57
• 15 Gogia A, Deo SVS, Sharma D. et al. Clinicopathologic characteristics and treatment outcomes of patients with up-front metastatic breast cancer: single-center experience in India. J Glob Oncol 2019; 5: 1-9
• 16 Sirohi B, Arnedos M, Popat S. et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008; 19 (11) 1847-1852
• 17 Tutt A, Tovey H, Cheang MCU. et al. A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and pre-specified triple negative breast cancer “BRCAness” subgroups: the TNT trial. Nat Med 2018; 24: 628-637
• 18 Hu X-C, Zhang J, Xu BH. et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2015; 16 (04) 436-446
• 19 Pandy JGP, Balolong-Garcia JC, Cruz-Ordinario MVB, Que FVF. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. BMC Cancer 2019; 19 (01) 1065
• 20 Petrelli F, Barni S, Bregni G, de Braud F, Di Cosimo S. Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials. Breast Cancer Res Treat 2016; 160 (03) 425-437
• 21 Robson M, Im SA, Senkus E. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017; 377 (06) 523-533
• 22 Litton JK, Rugo HS, Ettl J. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018; 379 (08) 753-763
• 23 O'Shaughnessy J, Schwartzberg L, Danso MA. et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014; 32 (34) 3840-3847
• 24 Schmid P, Adams S, Rugo HS. et al; IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018; 379 (22) 2108-2121